A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series

被引:24
作者
Martinez-Castellanos, Maria A. [1 ]
Leon, Ana Gonzalez-H [1 ]
Romo-Aguas, Juan C. [1 ]
Gonzalez-Gonzalez, Luis A. [2 ]
机构
[1] Hosp Luis Sanchez Bulnes IAP, Retina Serv Asociac Evitar Ceguera Mexico, Vicente Garcia Torres 46, San Lucas Coyoacan 04030, Ciudad De Mexic, Mexico
[2] Weill Cornell Med, Retina Serv, Dept Ophthalmol, 1305 Yolk Ave 11th Floor, New York, NY USA
关键词
Retinopathy of prematurity; Bevacizumab; Vitrectomy; Laser photocoagulation; Fluorescein angiography; INTRAVITREAL BEVACIZUMAB; EFFICACY;
D O I
10.1007/s00417-020-04605-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To provide a diagnostic algorithm of recurrence and treatment failure after intravitreal bevacizumab (IVB) injection for retinopathy of prematurity type 1 (ROP1) and the stepwise therapeutic approach for both conditions. Methods Retrospective chart review of all patients diagnosed with ROP1 initially treated with IVB in 6 tertiary referral centers of Toluca and Mexico City from 2005 to 2017. Treatment failure was defined as persistence or progression of neovascularization, elevation of the ridge, worsening of plus disease, or retinal crunch within the first week after treatment. Recurrence was defined as the new appearance of plus disease, an elevated ridge, or pathological new vessels after an initial regression of ROP following treatment. Therapy was observation, switch of anti-VEGF agent, retinal photocoagulation, vitrectomy, or a combination of two or more, depending on the severity of findings. Results A total of 672 patients who received intravitreal bevacizumab injection for ROP1 treatment were included. Of these, 2.5% (17 patients) failed to treatment, 6.8% (46 patients) developed a recurrence for ROP, and 5.5% (37 patients) carried a misdiagnosis of recurrence and were diagnosed with other than ROP1 after examination. Based on the severity of findings, patients with recurrence or treatment failure were further treated by observation, repeat anti-VEGF intravitreal injection (bevacizumab or other), laser photocoagulation, vitrectomy, or a combination of these. Based on the treatment results, a therapeutic algorithm was created. Conclusions Intravitreal injection of anti-VEGFs for the treatment of ROP warrants close follow-up as some of these patients may have treatment failure or recurrence of the disease. It is crucial to differentiate between them to avoid a misdiagnosis and offer the correct treatment. We propose a novel algorithm for the follow-up and treatment approach of ROP1 following initial treatment with IVB. This algorithm offers a summary of our recommendations based on a large case series of ROP1 patients. It is meant to grow and expand as more clinical evidence becomes available.
引用
收藏
页码:767 / 772
页数:6
相关论文
共 15 条
[1]   The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge [J].
Cavallaro, Giacomo ;
Filippi, Luca ;
Bagnoli, Paola ;
La Marca, Giancarlo ;
Cristofori, Gloria ;
Raffaeli, Genny ;
Padrini, Letizia ;
Araimo, Gabriella ;
Fumagalli, Monica ;
Groppo, Michela ;
Dal Monte, Massimo ;
Osnaghi, Silvia ;
Fiorini, Patrizio ;
Mosca, Fabio .
ACTA OPHTHALMOLOGICA, 2014, 92 (01) :2-20
[2]   Involution of retinopathy of prematurity after laser treatment: Factors associated with development of retinal detachment [J].
Coats, DK ;
Miller, AM ;
Hussein, MAW ;
McCreery, KMB ;
Holz, E ;
Paysse, EA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2005, 140 (02) :214-222
[3]  
Cryotherapy for Retinopathy of Prematurity Cooperative Group, 2012, ACHIVES OPHTHALMOL, V123, P1
[4]   Retinal vascular changes in preterm infants: heart and lung diseases and plus disease [J].
Elizabeth Arriola-Lopez, Andrea ;
Elena Martinez-Perez, M. ;
Ana Martinez-Castellanos, Maria .
JOURNAL OF AAPOS, 2017, 21 (06) :488-491
[5]  
Good WV., 2004, T AM OPHTHAL SOC, V102, P1684
[6]   Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity [J].
Karkhaneh, Reza ;
Khodabande, Alireza ;
Riazi-Eafahani, Mohammad ;
Roohipoor, Ramak ;
Ghassemi, Fariba ;
Imani, Marjan ;
Farahani, Afsar Dastjani ;
Adib, Nazanin Ebrahimi ;
Torabi, Hamidreza .
ACTA OPHTHALMOLOGICA, 2016, 94 (06) :E417-E420
[7]   Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure [J].
Martinez-Castellanos M.A. ;
Velez-Montoya R. ;
Price K. ;
Henaine-Berra A. ;
García-Aguirre G. ;
Morales-Canton V. ;
Cernichiaro-Espinosa L.A. .
International Journal of Retina and Vitreous, 3 (1)
[8]   Efficacy of Intravitreal Bevacizumab for Stage 3+Retinopathy of Prematurity. [J].
Mintz-Hittner, Helen A. ;
Kennedy, Kathleen A. ;
Chuang, Alice Z. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (07) :603-615
[9]  
O'Keeffe N, 2016, IRAN MED J, V81, P6
[10]   A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity [J].
Pertl, Laura ;
Steinwender, Gernot ;
Mayer, Christoph ;
Hausberger, Silke ;
Poeschl, Eva-Maria ;
Wackernagel, Werner ;
Wedrich, Andreas ;
El-Shabrawi, Yosuf ;
Haas, Anton .
PLOS ONE, 2015, 10 (06)